6 Gut Bacteria Species Show Protective Links Against Lung Cancer in New MR Study

For anyone who has spent time wondering whether their gut health connects to something beyond digestion, a new study adds a striking data point: the bacteria living in your intestines may influence your risk of lung cancer, and they appear to do it by shaping how your immune system behaves. This is early-stage science, not a clinical roadmap, but the mechanism it sketches is specific enough to be worth understanding.

Key takeaways:

• Six gut bacteria genera were associated with lower non-small cell lung cancer risk in a genetic study
• The protection linked to one genus, Peptococcus, appears to run partly through immune cells
• This is emerging evidence from a modelling approach, not a clinical trial; no supplement or diet is proven to replicate the effect
• The gut-lung axis (the biological pathway linking intestinal microbes to lung immunity) is increasingly supported by genetic data

Six Gut Bacteria Genera Associated with Lower NSCLC Risk

A two-step, two-sample Mendelian randomization study by Liu, Li, and Shao identified six gut bacterial genera whose higher abundance in the gut is genetically associated with a reduced risk of non-small cell lung cancer (NSCLC), the most common form of lung cancer. The six genera are Bacteroides, Roseburia, Alistipes, Methanobrevibacter, Ruminococcus gauvreauii group, and Peptococcus. Of these, Bacteroides showed the strongest signal: people whose genetics predicted higher Bacteroides levels had about 39% lower odds of developing NSCLC (OR = 0.610). Peptococcus also carried a statistically significant protective association (OR = 0.790). These are associations inferred from genetic data, not from tracking what people ate or measuring their microbiomes directly, which matters enormously for how to interpret them.

Why Lung Cancer Patients and High-Risk Individuals Should Pay Attention

NSCLC accounts for roughly 85% of all lung cancer diagnoses, and despite advances in targeted therapy and immunotherapy, outcomes remain poor for many patients. Research on the gut microbiota and cancer development has grown rapidly in recent years, with dysbiosis (an imbalance in gut microbial communities) linked to changes in systemic inflammation and immune function. The immune microenvironment surrounding tumors is now understood to be a key driver of whether a cancer grows, spreads, or responds to treatment. What this study adds is a genetic argument that the gut may be upstream of that immune environment, at least in part. For someone with a smoking history, a family history of lung cancer, or a personal interest in the lung-immune connection, the gut-lung axis is a direction worth following in the research literature.

How Mendelian Randomization Builds a Causal Argument

Mendelian randomization (MR) is a statistical method that uses naturally occurring genetic variants as proxies for an exposure, in this case gut bacteria abundance, to estimate whether that exposure causally affects a health outcome. Because genes are assigned at conception rather than shaped by lifestyle or disease, MR largely sidesteps the reverse-causation problem that plagues observational studies: you cannot argue that lung cancer caused someone to have more Bacteroides if the Bacteroides levels are predicted by genetic variants present from birth. The researchers selected 1,531 genetic variants (single nucleotide polymorphisms, or SNPs) as instruments for 119 gut bacterial genera, another 13,318 SNPs for 731 immune cell traits, and 9 SNPs for NSCLC itself. Their primary analytical tool was the Inverse Variance Weighted (IVW) method, a standard MR approach that pools evidence across multiple genetic instruments. The two-step design then asked a second question: do immune cells sit in the causal pathway between gut bacteria and NSCLC?

Immune Cells Act as the Middleman in the Gut-Lung Connection

The most mechanistically interesting finding concerns Peptococcus and a specific immune cell marker called CD45 on HLA DR+ CD4+ T cells (a surface protein on a class of immune-regulating white blood cells). The analysis found that this immune cell trait mediated 14.4% of Peptococcus's total protective association with NSCLC. In plain terms: part of the reason higher Peptococcus is associated with lower lung cancer risk appears to be that it influences how a particular subset of immune cells behaves. The gut-lung axis, the biological pathway by which intestinal microbes communicate with lung tissue, is thought to work partly through short-chain fatty acids (SCFAs), small molecules produced when gut bacteria ferment dietary fiber. SCFAs can activate innate lymphoid cells, regulatory T cells, and Th2 cells (types of immune cells that help regulate inflammation and the body's response to abnormal cells). This study's genetic evidence lines up with that mechanistic picture, though it does not prove the SCFA pathway specifically.

What This Means If You Are Managing Your Own Health

It is tempting to read findings like these as a call to take a probiotic or eat more fiber, and the logic is not entirely wrong. Dietary fiber is the primary fuel source for bacteria like Bacteroides and Roseburia. Research on plant-based diets and cancer prevention suggests that fiber-rich eating patterns may help regulate inflammation and hormone metabolism. Separate work on diet and the breast microbiome found that a Mediterranean diet increased beneficial bacteria in ways associated with reduced tumor growth in preclinical models. But it would be a mistake to treat those findings as proof that eating more fiber will lower your lung cancer risk: the chain of evidence from genetic association to dietary intervention to clinical outcome is long and has not been closed. What is reasonable is to mention this emerging literature to a physician, particularly if you are in a high-risk group, and to watch for clinical trials that test whether microbiome-targeted interventions affect lung cancer outcomes or immunotherapy response.

Key Limitations of This Mendelian Randomization Study

MR studies carry real limitations. The genetic variants used as instruments explain only a fraction of variation in gut bacteria abundance, which can reduce statistical power. The populations used for the GWAS data (large genetic databases including the Dutch Microbiome Project and the TRICL/ILCCO lung cancer consortia) are predominantly European, limiting how broadly the findings generalize. The mediation analysis, which identified the 14.4% immune cell effect, also assumes no unmeasured variables link the genetic instruments to the outcome through pathways other than the gut microbiome, an assumption that cannot be fully verified. The study also does not establish which specific bacterial metabolites or signalling molecules drive the immune cell changes. These are standard caveats for MR, but they are real: this evidence is best described as directional and hypothesis-generating.

What Comes Next in Gut-Lung Axis Research

The researchers point to bidirectional MR analyses as an important next step, to determine whether NSCLC also influences gut microbiome composition (it may: cancer and its treatments can disrupt the gut dramatically). Clinical researchers are also increasingly exploring whether gut microbiome composition predicts response to immune checkpoint inhibitors, the immunotherapy drugs now standard in many NSCLC treatment plans. If specific genera like Peptococcus or Bacteroides turn out to predict which patients respond to immunotherapy, that would create a concrete clinical application for findings like these. For now, this study adds genetic weight to a growing body of evidence that the gut and lungs are in active biological conversation, and that some of that conversation is mediated by the immune system.

Common Questions

Does this mean gut bacteria cause lung cancer or prevent it? The study found genetic associations suggesting that higher levels of six bacterial genera are linked to lower NSCLC risk. It supports a causal direction using MR methodology, but it is not a randomized trial proving that changing your gut bacteria prevents lung cancer.

Can taking probiotics boost these protective bacteria? The study does not test probiotics or any dietary intervention. The genera identified (such as Bacteroides and Roseburia) are influenced by diet, particularly fiber intake, but whether supplementing them would replicate the genetic associations found here is unknown and untested.

What is the gut-lung axis? The gut-lung axis is the biological communication pathway between intestinal microbes and lung tissue, thought to work through immune signals and metabolites like short-chain fatty acids that travel through the bloodstream and influence immune cell behavior in distant organs including the lungs.

References

1. Jiabin Chen, Xuzhou Yu, XiaoYu Wu, Kequn Chai, Sheng Wang (2024). Causal relationships between gut microbiota, immune cell, and Non-small cell lung cancer: a two-step, two-sample Mendelian randomization study. Journal of Cancer. https://doi.org/10.7150/jca.92699
2. Rashid Mir, Shrooq A. Albarqi, Wed Albalawi, et al. (2024). Emerging Role of Gut Microbiota in Breast Cancer Development and Its Implications in Treatment. Metabolites. https://doi.org/10.3390/metabo14120683
3. The Immune Microenvironment of Breast Cancer Progression – PMC – NIH. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747201/
4. Saee Deshpande (2025). Mendelian randomization studies: A unique research design. Journal of Advances in Dental Practice and Research. https://doi.org/10.25259/jadpr_31_2025
5. Martina Pontillo, Rossella Trio, Nicola Rocco, et al. (2025). Dietary Interventions for Breast Cancer Prevention: Exploring the Role of Nutrition in Primary and Tertiary Prevention Strategies. Healthcare. https://doi.org/10.3390/healthcare13040407
6. New Evidence Found for Role of Diet in Breast Health – Atrium Health Wake Forest Baptist. wakehealth.edu. https://www.wakehealth.edu/news/news-releases/2023/10/new-evidence-found-for-role-of-diet-in-breast-health
7. Heping Zhang (2023). Pros and cons of Mendelian randomization. Fertility and Sterility. https://doi.org/10.1016/j.fertnstert.2023.03.029